Extreme Drug Resistance in Primary Brain Tumors: in vitro Analysis of 64 Resection Specimens

[1]  Howard A. Fine,et al.  The basis for current treatment recommendations for malignant gliomas , 2005, Journal of Neuro-Oncology.

[2]  M. Prados,et al.  A phase II study of intravenous carboplatin for the treatment of recurrent gliomas , 2005, Journal of Neuro-Oncology.

[3]  J. Crowley,et al.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study , 2005, Journal of Neuro-Oncology.

[4]  Y. Ushio,et al.  Chemotherapy of malignant gliomas , 2005, Neurosurgical Review.

[5]  A. Kyritsis.  Chemotherapy for meningiomas , 1996, Journal of Neuro-Oncology.

[6]  M. Berger,et al.  Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure , 1992, Journal of Neuro-Oncology.

[7]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[8]  R. Hammond,et al.  Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. , 1999, Neurosurgery.

[9]  J. Smirniotopoulos.  The new WHO classification of brain tumors. , 1999, Neuroimaging clinics of North America.

[10]  K. Hosoya,et al.  The blood-brain barrier efflux transporters as a detoxifying system for the brain. , 1999, Advanced drug delivery reviews.

[11]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[12]  B. Kupelnick,et al.  Platinum analogues in the treatment of recurrent high grade astrocytoma. , 1998, Cancer treatment reviews.

[13]  M. Chamberlain,et al.  Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Bruner,et al.  The Treatment of Recurrent Unresectable and Malignant Meningiomas with Interferon Alpha-2B. , 1997, Neurosurgery.

[15]  S. Piantadosi,et al.  Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H Kalimo,et al.  Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. , 1997, Neurosurgery.

[17]  R. Fahlbusch,et al.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. , 1997, Journal of neurosurgery.

[18]  R. Fahlbusch,et al.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. , 1997, Journal of neurosurgery.

[19]  J. Bruner,et al.  The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. , 1997, Neurosurgery.

[20]  Y. Oshika,et al.  Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts. , 1997, British Journal of Cancer.

[21]  I. Cree,et al.  Tumor chemosensitivity and chemoresistance assays , 1996, Cancer.

[22]  M. Berger,et al.  Phase II study of paclitaxel in patients with recurrent malignant glioma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Cairncross Jg,et al.  Chemotherapy for malignant gliomas. , 1996 .

[24]  M. Markman,et al.  Tumor chemosensitivity and chemoresistance assays , 1996, Cancer.

[25]  M. Chamberlain,et al.  Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[27]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.

[28]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[30]  R. Larsson,et al.  Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. , 1993, Anticancer research.

[31]  B. Scheithauer,et al.  The New WHO Classification of Brain Tumours , 1993, Brain pathology.

[32]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[33]  J. Bruner,et al.  The treatment of anaplastic oligodendrogliomas and mixed gliomas. , 1993, Neurosurgery.

[34]  R. Tamargo,et al.  Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. , 1993, Cancer research.

[35]  David W. Smith,et al.  The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. , 1992, Journal of neurosurgery.

[36]  W. Yung,et al.  Intravenous carboplatin for recurrent malignant glioma: a phase II study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. G. Bosanquet.  Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay , 1991, The Lancet.

[38]  A. Friedman,et al.  Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. , 1991, Journal of neurosurgery.

[39]  A. Abbondandolo,et al.  O6-alkylguanine-DNA alkyltransferase activity in human brain tumors. , 1990, Cancer letters.

[40]  D. Kern,et al.  Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. , 1990, Journal of the National Cancer Institute.

[41]  B. Teicher,et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.

[42]  D. D. Hoff,et al.  He's not going to talk about in vitro predictive assays again, is he? , 1990, Journal of the National Cancer Institute.

[43]  D. V. Von Hoff.  He's not going to talk about in vitro predictive assays again, is he? , 1990, Journal of the National Cancer Institute.

[44]  R. Pieters,et al.  Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. , 1988, Cancer letters.

[45]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[46]  A. G. Bosanquet,et al.  Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. , 1986, Leukemia research.

[47]  V. Sondak,et al.  Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. , 1985, Cancer research.

[48]  M. Staquet,et al.  Predictive tests for the response to cancer chemotherapy: limitations related to the prediction of rare events. , 1984, Cancer treatment reports.

[49]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[50]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[51]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[52]  V. Levin,et al.  Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. , 1980, Cancer treatment reports.

[53]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[54]  D. Alberts,et al.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. , 1978, The New England journal of medicine.

[55]  A. Hamburger,et al.  Primary bioassay of human tumor stem cells. , 1977, Science.

[56]  B. Hoogstraten,et al.  CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea, NSC‐79037) in the treatment of cancer. Phase II study , 1973, Cancer.

[57]  V. Devita,et al.  Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu) , 1973 .

[58]  E. Boldrey,et al.  The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. , 1972, JAMA.

[59]  C. Smart,et al.  Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases. , 1968, Cancer chemotherapy reports.

[60]  T J Vecchio,et al.  Predictive value of a single diagnostic test in unselected populations. , 1966, The New England journal of medicine.